Cancers,
Journal Year:
2023,
Volume and Issue:
15(22), P. 5358 - 5358
Published: Nov. 10, 2023
To
assess
the
impact
of
COVID-19
pandemic
on
diagnosis,
staging
and
outcome
a
selected
population
throughout
first
two
years
pandemic,
we
evaluated
oncology
patients
undergoing
PET/CT
at
our
institution.
A
retrospective
lung
cancer,
melanoma,
lymphoma
head
neck
cancer
staged
using
during
6
months
2019,
2020
2021
were
included
for
analysis.
The
year
in
which
PET
was
performed
exposure
variable,
main
outcomes
stage
time
overall
survival
(OS).
total
1572
PET/CTs
purposes
2021.
median
age
66
(IQR
16),
915
(58%)
males.
most
prevalent
(643,
41%).
univariate
analysis
OS
by
not
significantly
different.
multivariate
Cox
regression
non-COVID-19
different
variables
determined
that
(HR
1.76
CI95
1.23-2.53,
p
<
0.05),
III
3.63
2.21-5.98,
IV
11.06
7.04-17.36,
0.05)
diagnosis
1.04
1.02-1.05,
had
increased
risks
death.
We
did
find
higher
stages
or
reduced
when
assessing
performed.
Furthermore,
modified
staged,
even
controlled
significant
(age,
type
gender).
Acta Oncologica,
Journal Year:
2025,
Volume and Issue:
64, P. 156 - 166
Published: Jan. 28, 2025
Background
and
purpose:
Coronavirus
disease
2019
(COVID-19)
caused
a
need
for
reorganization
in
the
healthcare
systems.
First,
we
aimed
to
determine
impact
of
COVID-19
pandemic
on
time
treatment
head
neck
cancer
(HNC)
patients.
Second,
tumor
stage
changes
regimens
used.
Material
methods:
A
systematic
search
PubMed
Embase
was
conducted
according
Preferred
Reporting
Items
Systematic
Reviews
Meta-Analyses
guidelines.
Inclusion
criteria
were:
(1)
Studies
including
patients
with
squamous
cell
carcinomas;
(2)
containing
comparison
treatment;
(3)
well-defined
interval
restrictions
health
care
due
without
restrictions.
Results:
total
19
studies
were
included
comprising
24,898
treated
HNC
cancer.
Six
(10.1%
patients)
reported
an
increase
waiting
within
at
least
one
interval,
while
seven
decrease
(83.2%
patients),
six
found
no
significant
effect.
No
modalities
observed.
Seven
15
(12.7%
observed
either
overall
stage,
size,
or
node
metastasis
classification
during
pandemic.
Among
these,
two
increased
times
as
well.
Interpretation:
The
COIVD-19
heterogenous
subject
considerable
intercountry
interregional
variations.
tendency
toward
higher
T-classification
In
conclusion,
otorhinolaryngology
departments
demonstrated
resilience,
led
only
slight
alterations
treatment.
BMC Cancer,
Journal Year:
2024,
Volume and Issue:
24(1)
Published: Jan. 29, 2024
Abstract
Background
The
COVID-19
pandemic
might
have
delayed
cancer
diagnosis
and
management.
aim
of
this
systematic
review
was
to
compare
the
initial
tumor
stage
new
diagnoses
before
after
pandemic.
Methods
We
systematically
reviewed
articles
that
compared
solid
waves.
conducted
a
random-effects
meta-analysis
rate
metastatic
tumors
distribution
stages
at
diagnosis.
Subgroup
analyses
were
performed
by
primary
site
country.
Results
From
2,013
studies
published
between
January
2020
April
2022,
we
included
58
with
109,996
patients.
higher
outbreak
than
(pooled
OR:
1.29
(95%
CI,
1.06-1.57),
I
2
:
89%
86-91)).
For
specific
cancers,
common
ORs
reached
statistical
significance
for
breast
(OR:
1.51
CI
1.07-2.12))
gynecologic
1.04-2.18))
but
not
other
types.
According
countries,
OR
CI)
only
Italy:
1.55
(1.01-2.39)
Spain:1.14
(1.02-1.29).
Rates
comparable
I-II
versus
III-IV
in
which
information
available,
III
did
include
Conclusions
Despite
inter-study
heterogeneity,
our
showed
burden
social
distancing
policies
explain
those
results,
as
patients
may
seeking
care.
Clinical Otolaryngology,
Journal Year:
2024,
Volume and Issue:
49(4), P. 363 - 375
Published: March 21, 2024
Abstract
Objectives
This
rapid
review
aims
to
evaluate
the
impact
of
COVID‐19
pandemic
on
incidence
head
and
neck
cancer
(HNC)
stage
distribution
at
diagnosis.
Design
Rapid
meta‐analysis.
Participants
Comparative
data
for
new
HNC
patients
between
a
pre‐pandemic
cohort
(before
March
2020)
(after
2020
during
lockdown
period).
Main
Outcomes
Measured
Data
tumour
stage,
incidence,
referral
pathway
(number
patient
referrals),
or
workload
levels
treatments).
were
summarised
as
odds
ratios
(OR)
with
95%
confidence
intervals
(CI),
related
changes
in
numbers
diagnoses,
referrals,
narrative
synthesis.
Results
A
total
31
reports
included
this
review.
Individually
16
out
23
studies
did
not
show
significant
relative
period.
However,
meta‐analysis
revealed
that
diagnosed
16%
more
likely
have
nodal
involvement
(OR
=
1.16;
CI
1.00–1.35),
17%
late
overall
1.17;
1.01–1.36),
32%
present
advanced
extent
(T3
T4
stage)
1.32;
1.08–1.62).
was
extremely
limited
currently
sufficient
assess
trends
burden
disease.
Conclusions
indicates
pandemic,
there
upstaging
diagnosis,
suggesting
provision
care
significantly
affected.
Journal of Clinical Medicine,
Journal Year:
2025,
Volume and Issue:
14(5), P. 1424 - 1424
Published: Feb. 20, 2025
Background/Objectives:
The
COVID-19
pandemic
led
to
unprecedented
disruptions
cancer
care,
including
the
care
of
head
and
neck
cancer.
Given
necessity
timely
treatment
for
mucosal
cancers,
it
is
important
understand
how
affected
diagnosis,
presentation,
Methods:
National
Cancer
Database
was
queried
patients
with
primary
number
annual
diagnoses
days
between
diagnosis
start
end
any
were
tracked
over
time
from
2004
2020.
Chi-square
tests
used
compare
differences
in
patient
clinical
demographic
characteristics
2019
2020
provide
most
direct
comparison.
Multivariable
linear
regression
logic
analyses
also
three
quality
measures
2020:
treatment,
surgery
postoperative
radiation,
radiation.
Results:
decreased
(9.1%)
during
early
stages
pandemic,
a
larger
decrease
(12.4%)
among
receiving
surgery.
On
multivariable
analysis
comparing
2019,
shorter
(2.3
days;
95%
CI,
1.69
2.85
days),
radiation
less
likely
be
delayed
(OR,
0.91
greater
than
42
surgery;
0.85
0.97).
However,
who
black,
female,
older,
or
uninsured
more
experience
delays.
Conclusions:
Overall,
there
no
delays
surgical
pandemic.
vulnerable
groups,
such
as
uninsured,
at
higher
risk
experiencing
Head & Neck,
Journal Year:
2024,
Volume and Issue:
46(9), P. 2197 - 2205
Published: April 25, 2024
Abstract
Background
The
causes
for
delays
during
the
COVID19
pandemic
and
their
impact
on
head
neck
cancer
(HNC)
diagnosis
staging
are
not
well
described.
Methods
Two
cohorts
were
defined
a
priori
review
analysis—a
Pre‐Pandemic
cohort
(June
1
to
December
31,
2019)
Pandemic
2020).
Delays
categorized
as
COVID‐19
related
or
not,
clinician,
patient,
policy
related.
Results
A
total
of
638
HNC
patients
identified
including
327
in
Cohort
311
Cohort.
Patients
had
more
N2‐N3
category
(41%
vs.
33%,
p
=
0.03),
T3‐T4
(63%
50%,
0.002),
stage
III‐IV
(71%
58%,
<
0.001)
disease.
Several
intervals
treatment
pathway
significantly
longer
compared
cohort.
Among
cohort,
146
(47%)
experienced
delay,
with
112
pandemic;
80
(71%)
clinician
related,
15
(13%)
patient
17
(15%)
Conclusions
higher
disease
at
along
diagnostic
pathway,
factors
being
most
common
cause
delay.
